评价川芎嗪、丹参联合强的松治疗特发性肺纤维化的疗效

中国医师进修杂志 Pub Date : 2001-01-15 DOI:10.3760/CMA.J.ISSN.1673-4904.2001.01.009

J. Hou, L. Dai

{"title":"评价川芎嗪、丹参联合强的松治疗特发性肺纤维化的疗效","authors":"J. Hou, L. Dai","doi":"10.3760/CMA.J.ISSN.1673-4904.2001.01.009","DOIUrl":null,"url":null,"abstract":"Objective:Use ligustrazin and salvia miltiorrhiza to treat idiopathic pulmonary fibrosis,for the experimental result was perfect in animal modal.Method:These two drugs combined with prednisone in 15 patients as treated group,prednisone in 10 patients as control group.Result:At 1,6 months followed up,the dyspnea and cough improved markedly.Chest radiograph and pulmonary function improved slightly.There were no differences between two groups.After 24 month the combined group 13(73%) stabilized,4(27%) relapse or deterioration,no death.Control group 6(60%) stabilized,3(30%) relapse or deterioration,1(10%) death,Conclusion:Combined group was better then control group.Ligustrazin and salvia miltorrhiza could decrease alveolitis and inhibit the formation of procollagen.It also improve the patient's immunity.","PeriodicalId":10229,"journal":{"name":"中国医师进修杂志","volume":"14 1","pages":"17-18"},"PeriodicalIF":0.0000,"publicationDate":"2001-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"TO EVALUATE THE EFFICACY OF LIGUSTRAZIN AND SALVIA MILTIORRHIZA COMBINED PREDNISONE TO TREAT IDIOPATHIC PULMONARY FIBROSIS\",\"authors\":\"J. Hou, L. Dai\",\"doi\":\"10.3760/CMA.J.ISSN.1673-4904.2001.01.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective:Use ligustrazin and salvia miltiorrhiza to treat idiopathic pulmonary fibrosis,for the experimental result was perfect in animal modal.Method:These two drugs combined with prednisone in 15 patients as treated group,prednisone in 10 patients as control group.Result:At 1,6 months followed up,the dyspnea and cough improved markedly.Chest radiograph and pulmonary function improved slightly.There were no differences between two groups.After 24 month the combined group 13(73%) stabilized,4(27%) relapse or deterioration,no death.Control group 6(60%) stabilized,3(30%) relapse or deterioration,1(10%) death,Conclusion:Combined group was better then control group.Ligustrazin and salvia miltorrhiza could decrease alveolitis and inhibit the formation of procollagen.It also improve the patient's immunity.\",\"PeriodicalId\":10229,\"journal\":{\"name\":\"中国医师进修杂志\",\"volume\":\"14 1\",\"pages\":\"17-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2001-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国医师进修杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-4904.2001.01.009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国医师进修杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4904.2001.01.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

目的:用川芎嗪联合丹参治疗特发性肺纤维化，动物模型实验结果较好。方法:两种药物联合强的松治疗15例，强的松治疗10例。结果:随访1 ~ 6个月，呼吸困难、咳嗽明显好转。胸片和肺功能略有改善。两组之间没有差异。24个月后，联合组13例(73%)病情稳定，4例(27%)复发或恶化，无死亡。对照组患者病情稳定6例(60%)，复发或恶化3例(30%)，死亡1例(10%)。结论:联合组优于对照组。川芎嗪和丹参均能减轻肺泡炎，抑制前胶原的形成。它还能提高病人的免疫力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

TO EVALUATE THE EFFICACY OF LIGUSTRAZIN AND SALVIA MILTIORRHIZA COMBINED PREDNISONE TO TREAT IDIOPATHIC PULMONARY FIBROSIS

Objective:Use ligustrazin and salvia miltiorrhiza to treat idiopathic pulmonary fibrosis,for the experimental result was perfect in animal modal.Method:These two drugs combined with prednisone in 15 patients as treated group,prednisone in 10 patients as control group.Result:At 1,6 months followed up,the dyspnea and cough improved markedly.Chest radiograph and pulmonary function improved slightly.There were no differences between two groups.After 24 month the combined group 13(73%) stabilized,4(27%) relapse or deterioration,no death.Control group 6(60%) stabilized,3(30%) relapse or deterioration,1(10%) death,Conclusion:Combined group was better then control group.Ligustrazin and salvia miltorrhiza could decrease alveolitis and inhibit the formation of procollagen.It also improve the patient's immunity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国医师进修杂志

自引率

0.00%

发文量

26239

期刊介绍： Chinese Journal of Postgraduates of Medicine (founded in 1978, monthly) is one of the series of journals of the Chinese Medical Association (CMA) under the supervision of the National Health Commission of the People's Republic of China, sponsored by the Chinese Medical Association (CMA) and Dalian Institute of Theoretical Medicine (DITM). It is a core journal of Chinese science and technology, a statistical source journal of Chinese scientific and technical papers, and a statistical source journal of China Academic Journal Impact Factor Annual Report. The journal adheres to the purpose of using continuing medical education and post training, highlights new theories, new knowledge, new methods and new technologies, and focuses on the combination of theory and practice, and the combination of popularisation and improvement. Main columns: Special tutorials, expert forums, clinical treatises, clinical experience, reviews and lectures, continuing medical education, teaching and research, advanced training forum, drugs and clinics, overview of progress, introduction of new technologies, imaging and clinics, lessons learnt, discussions and evaluations, case reports, discussions of clinical cases, conference proceedings, and domestic and international academic developments. The main target readers are clinical medical personnel in internal medicine, surgery, gynaecology, paediatrics and ophthalmology.